About Braeburn
Braeburn is a company based in Philadelphia (United States) founded in 2012. Braeburn has raised $110 million across 2 funding rounds from investors including New Leaf Venture Partners, RA Capital and Wellington. Braeburn offers products and services including OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs. Braeburn operates in a competitive market with competitors including Avidity Biosciences, Univercells, Indivior, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Philadelphia, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Braeburn Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$110 M (USD)
in 2 rounds
-
Latest Funding Round
$110 M (USD), Debt – Conventional
Jan 10, 2018
-
Investors
New Leaf Venture Partners
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Braeburn
Braeburn offers a comprehensive portfolio of products and services, including OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs.
Products for managing opioid use disorder and supporting recovery.
Series featuring stories to reduce stigma around addiction.
Programs partnering with organizations for opioid crisis response.
People of Braeburn
Unlock access to complete
Unlock access to complete
Funding Insights of Braeburn
Braeburn has successfully raised a total of $110M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $110 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Braeburn
Braeburn has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, RA Capital and Wellington.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Braeburn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Braeburn
Investment portfolio details for Braeburn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Braeburn
Detailed financials for Braeburn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Braeburn Comparisons
Peer comparison for Braeburn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Braeburn
Braeburn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Indivior, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Braeburn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Braeburn
Complete news archive for Braeburn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Braeburn
Braeburn was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Braeburn is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Mike Derkacz is the current CEO of Braeburn.
Braeburn is a funded company, having raised a total of $110M across 2 funding rounds to date.
Braeburn was founded in 2012 in Philadelphia, United States, within the biotechnology sector. Implantable and injectable formulations for treating opioid addiction and chronic pain are developed. The lead product, Probufine, a buprenorphine implant, has been approved by the FDA for opioid dependence. CAM2038 undergoes NDA refiling for opioid dependence and is in phase 3 trials for pain management, delivered subcutaneously via the proprietary FluidCrystal system.
Braeburn's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Braeburn offers OUD Treatment Products, Advocacy Docuseries, and Volunteer Programs.
Braeburn has 7 investors. Key investors include New Leaf Venture Partners, RA Capital, Wellington, Deerfield, and Rock Springs Capital.